North America Narcolepsy Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
to 2027 - Regional Analysis and Forecasts By Type (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy); Product (Central Nervous System (CNS) Stimulants, Sodium Oxybate, and Antidepressants); Distribution Channel (Hospital Pharmacies and Retail Pharmacies) and Country

No. of Pages: 118    |    Report Code: TIPRE00008100    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Narcolepsy Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Narcolepsy Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Narcolepsy Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Increase in the prevalence of sleep disorders
  • 5.1.2 Growing awareness of narcolepsy symptoms
5.2 Market Opportunities
  • 5.2.1 Growth in narcolepsy diagnostic services
  • 5.2.2 Expansion in treatment options
5.3 Future Trends
  • 5.3.1 Development of personalized treatment plans
  • 5.3.2 Increase in adoption of cognitive-behavioral therapy
5.4 Impact of Drivers and Restraints

6. North America Narcolepsy Market Regional Analysis

6.1 North America Narcolepsy Market Overview
6.2 North America Narcolepsy Market Revenue 2016-2027 (US$ Million)
6.3 North America Narcolepsy Market Forecast Analysis

7. North America Narcolepsy Market Analysis – by Type

7.1 Narcolepsy with Cataplexy
  • 7.1.1 Overview
  • 7.1.2 Narcolepsy with Cataplexy: North America Narcolepsy Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Narcolepsy without Cataplexy
  • 7.2.1 Overview
  • 7.2.2 Narcolepsy without Cataplexy: North America Narcolepsy Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Secondary Narcolepsy
  • 7.3.1 Overview
  • 7.3.2 Secondary Narcolepsy: North America Narcolepsy Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Narcolepsy Market Analysis – by Product

8.1 Central Nervous System Stimulants
  • 8.1.1 Overview
  • 8.1.2 Central Nervous System Stimulants: North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Sodium Oxybate
  • 8.2.1 Overview
  • 8.2.2 Sodium Oxybate: North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Antidepressants
  • 8.3.1 Overview
  • 8.3.2 Antidepressants: North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

9. North America Narcolepsy Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Antidepressants: North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Retail Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Antidepressants: North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10. North America Narcolepsy Market – North America Analysis

10.1 North America
  • 10.1.1 North America Narcolepsy Market Breakdown, by Key Country, 2019 and 2027 (%)
  • 10.1.1.1 North America Narcolepsy Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.1.1 US: North America Narcolepsy Market Breakdown, by Type
    • 10.1.1.1.2 US: North America Narcolepsy Market Breakdown, by Product
    • 10.1.1.1.3 US: North America Narcolepsy Market Breakdown, by Distribution Channel
  • 10.1.1.2 Canada: North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.2.1 Canada: North America Narcolepsy Market Breakdown, by Type
    • 10.1.1.2.2 Canada: North America Narcolepsy Market Breakdown, by Product
    • 10.1.1.2.3 Canada: North America Narcolepsy Market Breakdown, by Distribution Channel
  • 10.1.1.3 Mexico : North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Narcolepsy Market Breakdown, by Type
    • 10.1.1.3.2 Mexico : North America Narcolepsy Market Breakdown, by Product
    • 10.1.1.3.3 Mexico : North America Narcolepsy Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Narcolepsy Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Teva Pharmaceutical Industries Ltd.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Jazz Pharmaceuticals plc
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Arena Pharmaceuticals, Inc.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Graymark Healthcare, Inc.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Novartis AG
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Takeda Pharmaceutical Company Limited
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Mylan N.V.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 BIOPROJET
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Shionogi & Co., Ltd.
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Ligand Pharmaceuticals, Inc
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - North America Narcolepsy Market

The List of Companies - North America Narcolepsy Market

  1. Teva Pharmaceutical Industries Ltd.
  2. Jazz Pharmaceuticals plc
  3. Arena Pharmaceuticals, Inc.
  4. Graymark Healthcare, Inc.
  5. Novartis AG
  6. Takeda Pharmaceutical Company Limited
  7. Mylan N.V.
  8. BIOPROJET
  9. Shionogi & Co., Ltd.
  10. Ligand Pharmaceuticals, Inc

 

north-america-narcolepsy-market